Smith–Magenis syndrome (SMS; OMIM #182290) and Potocki–Lupski syndrome (PTLS; OMIM #610883) are rare neurodevelopmental disorders that underscore the critical role of dosage-sensitivity in the RAI1 gene in determining distinct clinical outcomes [2]. This evidence concerns the gene RAI1 and Potocki-Lupski syndrome.